Highlights

  • Pro Medicus Limited (ASX:PME) shares were trading at AUD 175.98, down 1.61% or AUD 2.88, at the time of writing on 17 August 2026, placing the healthcare technology company among the day’s top S&P/ASX 200 decliners.
  • PME remained 44.61% lower over the past year, providing a considerably weaker 12-month share-price backdrop.
  • The S&P/ASX 200 (ASX:XJO) was trading at 9,092.50 points, down 0.25% or 22.70 points, while Pro Medicus recorded a larger decline.
  • Pro Medicus is scheduled to release its FY26 full-year results on 18 August 2026, while its latest contract announcement involved a seven-year, AUD 23 million agreement with St. Luke’s Health System.

Pro Medicus Limited (ASX:PME) traded lower on Monday, placing the medical imaging technology company among the top S&P/ASX 200 decliners on 17 August 2026.

Pro Medicus shares were trading at AUD 175.98, down 1.61% or AUD 2.88, at the time of writing on 17 August 2026. The decline was larger than the broader Australian market movement, with the S&P/ASX 200 trading at 9,092.50 points, down 0.25% or 22.70 points.

The stock also remained 44.61% lower over the past year, highlighting a considerable reset in its longer-term share-price performance.

Daily price movements can reflect changes in valuation expectations, investor positioning and views about future earnings. However, a 1.61% decline does not mean the underlying Business changed by an equivalent amount during one session. For Pro Medicus, investors typically assess contract wins, implementation schedules, recurring transaction revenue, margins and expansion of the Visage platform.

Medical imaging technology at the core

Pro Medicus is a healthcare informatics company specialising in medical imaging software. Its main platform, Visage 7, is used by hospitals and healthcare organisations to manage and view medical images across large clinical networks.

The company’s offering includes image viewing, workflow and archive capabilities, while newer applications are broadening the platform beyond radiology. Pro Medicus has been developing cardiology capabilities and additional imaging applications as it seeks to increase its role across healthcare organisations.

An important feature of the business model is transaction-based pricing. Many contracts generate Revenue according to examination volumes, allowing revenue to increase as customers perform more imaging studies.

Pro Medicus has also emphasised cloud deployment. Large healthcare systems increasingly require platforms capable of managing substantial quantities of imaging data across multiple sites without maintaining separate systems for every hospital or specialty.

For investors, the ability to win large health networks and then expand services within existing customers remains an important part of the longer-term growth profile.

FY26 results are next

One of the most relevant near-term events for Pro Medicus investors is its FY26 full-year result.

The company has confirmed that its FY26 numbers will be released on 18 August 2026, one day after the share-price movement covered here. A management webcast is also scheduled for the same day.

That means FY26 full-year financial figures were not yet available at the time of writing on 17 August.

The latest reported financial period therefore remains H1'FY26. For the six months ended December 2025, revenue from ordinary activities increased 28.4% to AUD 124.8 million, while Underlying Profit before tax increased 29.7% to AUD 90.7 million. Underlying Net Profit After Tax reached AUD 67.3 million, also up 29.7%.

Underlying Earnings Before Interest and Tax Margin increased to 73% from 72%, while cash and other financial Assets reached AUD 221.8 million. Pro Medicus remained debt-free and declared a fully franked Interim Dividend of 32 cents per share.

The upcoming result will therefore provide investors with a clearer indication of whether those trends continued through the second half.

Contract pipeline continues to develop

Contract wins remain one of the most visible indicators of Pro Medicus’ commercial expansion.

On 12 August 2026, the company announced a seven-year, AUD 23 million contract with St. Luke’s Health System in the United States. The agreement covers Visage 7 Viewer and Visage 7 Workflow and will be implemented through the cloud. Go-live is targeted for Q1 of calendar year 2027.

The St. Luke’s agreement followed several other contracts during FY26.

In March, Pro Medicus announced two five-year contract renewals with a combined minimum value of AUD 40 million, comprising a AUD 31 million renewal with MedStar and a AUD 9 million renewal with Zwanger-Pesiri. The MedStar agreement also added Visage 7 Cardiology.

These agreements illustrate how Pro Medicus can generate opportunities both from new customers and existing relationships.

Contract value, however, does not necessarily translate immediately into revenue. Implementation schedules and transaction volumes determine how revenue is recognised over time, making successful deployments an important Factor to monitor.

What investors may watch in FY26 results

The upcoming full-year release gives investors several areas to assess.

Revenue growth will be one of the most obvious measures. New customers and implementations can expand transaction volumes, while additional modules can increase revenue generated from existing healthcare networks.

Margins will also attract attention. Pro Medicus operates a software-focused model with comparatively high operating margins, so investors may examine whether increased revenue continues to translate efficiently into earnings.

Cash generation and the Balance Sheet are also relevant. At December 2025, Pro Medicus remained debt-free with AUD 221.8 million of cash and other financial assets. This provides financial capacity for product development, dividends and selective investments.

Investors may additionally look for commentary on the North American sales pipeline. The US represents an important addressable market for Visage, and Pro Medicus has continued winning contracts across health systems of varying sizes.

Progress in cardiology and other clinical areas could also influence expectations. Extending Visage beyond radiology could increase the amount of imaging activity handled through the platform.

Valuation remains part of the discussion

The stock’s 44.61% decline over the past year makes valuation an important consideration when looking at PME.

Pro Medicus has historically attracted market attention because of its revenue growth, recurring transaction-based model, margins and growing US presence. However, expectations embedded in high-growth technology valuations can also make share prices sensitive when investors alter assumptions about future growth.

A lower share price does not automatically mean the business outlook has weakened to the same degree. Similarly, a significant historical decline does not by itself establish that a stock is inexpensive.

For Pro Medicus, longer-term valuation will depend on actual financial delivery: revenue generated from new contracts, implementation timing, customer retention, transaction volumes and continued expansion of its platform.

Final takeaway

Pro Medicus (ASX:PME) was among the top S&P/ASX 200 decliners on 17 August 2026, with shares trading at AUD 175.98, down 1.61% or AUD 2.88, at the time of writing on 17 August 2026. The stock remained 44.61% lower over the past year.

The S&P/ASX 200 was down 0.25% at 9,092.50 points.

Attention now turns to Pro Medicus’ FY26 results on 18 August. Investors are likely to focus on revenue and earnings growth, margins, cash generation, contract implementations and the expansion of Visage into additional clinical areas.

The latest daily fall puts PME among Monday’s notable decliners, but the upcoming financial results and future contract execution should provide more meaningful evidence of the company’s operating direction.